Literature DB >> 2223588

Elevated CA125 levels in patients with metastatic breast carcinoma.

L Perey1, D F Hayes, C Tondini, G van Melle, J Bauer, T Lemarchand, M Reymond, J P Mach, S Leyvraz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2223588      PMCID： PMC1971485          DOI： 10.1038/bjc.1990.353

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  20 in total

1.  Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen.

Authors:  D C Tormey; T P Waalkes; J J Snyder; R M Simon
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

2.  CA125 seric levels in non malignant pathologies.

Authors:  A Ruibal; G Encabo; E Martinéz-Miralles; C Murcia; J A Capdevila; A Salgado; J M Martinéz-Vasquéz
Journal:  Bull Cancer       Date:  1984       Impact factor: 1.276

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.

Authors:  C Tondini; D F Hayes; R Gelman; I C Henderson; D W Kufe
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

5.  Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer: a predictor and monitor of response and relapse.

Authors:  J J Lokich; N Zamcheck; M W Lowenstein
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

6.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

7.  Carcinoembryonic antigen in breast cancer.

Authors:  R E Myers; D J Sutherland; J W Meakin; J A Kellen; D G Malkin; A Malkin
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

8.  Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma.

Authors:  D E Haagensen; S J Kister; J P Vandevoorde; J B Gates; E K Smart; H J Hansen; S A Wells
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

9.  Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA).

Authors:  F Buchegger; C Mettraux; R S Accolla; S Carrel; J P Mach
Journal:  Immunol Lett       Date:  1982-08       Impact factor: 3.685

10.  Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

Authors:  P A Canney; M Moore; P M Wilkinson; R D James
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640
View more
  4 in total

1.  Mesorectum localization as a special kind of rectal metastasis from breast cancer.

Authors:  Fan Xue; Zhong-Lin Liu; Qing Zhang; Xiang-Nan Kong; Wen-Zhi Liu
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 2.  Promoting quality and evidence-based care in early-stage breast cancer follow-up.

Authors:  N Lynn Henry; Lynn N Henry; Daniel F Hayes; Scott D Ramsey; Gabriel N Hortobagyi; William E Barlow; Julie R Gralow
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

3.  CA-125 is not a useful marker in metastatic breast cancer.

Authors:  M J Seckl; G J Rustin; R C Coombes
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

4.  Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?

Authors:  W Jäger; A Kissing; S Cilaci; R Melsheimer; N Lang
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.